Charles Schwab
ADIL

Charles Schwab’s Adial Pharmaceuticals ADIL Stock Holding History

Charles Schwab’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34
Closed -$29K – 3509
2022
Q2 		$29K Buy
+34
New +$30.8K ﹤0.01% 3476
2022
Q1 		– Sell
-19
Closed -$32K – 3582
2021
Q4 		$32K Hold
19
– – ﹤0.01% 3543
2021
Q3 		$50K Buy
+19
New +$39.8K ﹤0.01% 3449

Other funds holding ADIL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Charles Schwab's ADIL Position: Q3 2022 in Review

Charles Schwab sold out of Adial Pharmaceuticals (ADIL) in Q3 2022, closing a stake of 34 shares — an estimated $29K sold.

Charles Schwab first reported a position in ADIL in Q3 2021 and held it in 3 quarters. The position peaked at $50K in Q3 2021. 25 funds tracked by Wall St. Rank hold ADIL as of Q3 2022.

  • Charles Schwab reported no remaining Adial Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Charles Schwab sold 34 Adial Pharmaceuticals shares in Q3 2022, an estimated $29K.
  • Charles Schwab first reported a position in Adial Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Charles Schwab's Adial Pharmaceuticals position peaked at $50K in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q3 2022.

Based on Charles Schwab's 13F filing for Q3 2022, filed 14 Nov 2022.